Is TRT FDA-Approved? What You Need to Know Before Starting

Short answer: FDA-approved testosterone products exist, but only for specific hypogonadism diagnoses — not general age-related decline. Much of telehealth TRT is compounded instead, which is legal but has not gone through the same FDA premarket review.

"TRT" gets used as a catch-all term, but not all testosterone therapy carries the same regulatory status. Some products are FDA-approved for specific, narrowly defined conditions. A lot of what's prescribed today is compounded instead — which is legal, but means something different. Here's the actual regulatory picture.

What FDA Approval for Testosterone Actually Covers

FDA-approved testosterone products — available as topical gel, transdermal patch, a buccal system applied to the gum or inner cheek, oral tablets, and injections — are approved only for men who have low testosterone alongside a specific, medically associated condition.^[1] They are not approved for men who simply have low testosterone without one of those conditions present.

The approved indication covers two categories. Primary hypogonadism means testicular failure — from causes like undescended testicles, testicular torsion, testicular infection, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. Hypogonadotropic hypogonadism means a deficiency in the hormones that signal the testes to produce testosterone, caused by pituitary or hypothalamic injury from tumors, trauma, or radiation.^[3] The two are distinguished biochemically: primary hypogonadism typically shows low testosterone with elevated LH/FSH, while hypogonadotropic hypogonadism shows low testosterone with LH/FSH in the normal or low range.^[3] Testosterone pellets (Testopel) carry one additional approved use beyond replacement therapy — stimulating puberty in carefully selected boys with clearly documented delayed puberty.^[5]

Why This Distinction Became a Regulatory Issue

This isn't a theoretical concern. In 2014, an FDA advisory panel voted nearly unanimously to recommend tightening testosterone labeling specifically because the ambiguous term "idiopathic" in earlier labels had contributed to widespread prescribing in men whose testosterone had never been properly tested or who had normal levels to begin with.^[6] That review is part of why current labeling draws such a clear line around approved use.

How Compounded TRT Fits Into This Picture

A large share of TRT prescribed through telehealth today is compounded rather than an FDA-approved finished product. Compounding is governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which exempt licensed pharmacists and physicians from three requirements that apply to FDA-approved drugs: the new drug approval process itself, mandatory FDA-approved labeling, and current Good Manufacturing Practice standards.^[7]Under 503A specifically, a compounding pharmacy can use a bulk drug substance if it meets a recognized pharmacopeial standard, is already a component of an FDA-approved drug, or appears on FDA's approved 503A bulk substances list — and because testosterone is already a component of multiple FDA-approved products, compounding pharmacies can generally use it under this pathway.^[8]

The practical consequence: compounded testosterone hasn't gone through FDA's premarket review for safety, efficacy, or manufacturing quality the way an approved product has, and it isn't required to carry FDA-approved labeling.^[9]That doesn't automatically mean it's unsafe — compounding is a long-standing, legal part of medicine — but it does mean the safety and efficacy assurances that come with FDA approval simply don't apply in the same way.

What a Major Independent Review Found

In 2020, the National Academies of Sciences, Engineering, and Medicine reviewed compounded bioidentical hormone therapy — a category that explicitly includes compounded testosterone cypionate and propionate — and concluded there is a lack of rigorous evidence for safety and effectiveness from well-designed, controlled clinical studies.^[10]The report found that most of the existing safety and effectiveness data on these preparations came from lower-quality sources — anecdotal reports, patient testimonials, and prescriber accounts — rather than controlled trials, and concluded there isn't sufficient evidence to say compounded preparations are as safe or effective as FDA-approved hormone therapy.^[10]Based on those findings, the committee recommended restricting compounded bioidentical hormone therapy use, and the FDA has said it's using this analysis to inform its ongoing approach to hormone compounding, including evaluating specific compounds for a forthcoming "difficult-to-compound" list.^[11]

The Bottom Line

FDA-approved testosterone products exist and work well for the specific conditions they're approved to treat — but they explicitly don't cover general age-related decline, and a large portion of what's prescribed today is compounded rather than FDA-approved. Neither fact makes TRT illegitimate. What it means practically is that it's worth knowing which one you're being offered, understanding that compounded products haven't been through the same FDA review process, and expecting any provider to be transparent about that distinction rather than blurring it.

Worth asking any provider directly whether the testosterone they prescribe is an FDA-approved product or a compounded preparation — compare how RENVA's Men's Health / TRT hub surfaces pharmacy transparency before choosing one.

Frequently Asked Questions